Trial Profile
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms C-SCADE-5
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 15 Sep 2017 Results of pooled analysis assessing safety of this and other phase I-III studies , presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 15 Sep 2017 Results of pooled safety analysis in >12,000 patients who were randomized to Empagliflozin (10 mg, 25 mg) or placebo in 15 Phase I-III trials plus 4 extension studies, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 16 Sep 2016 Results of a pooled analysis assessing risk of bone fracture presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes